For Physicians

Referrals
Presentations/Meetings
Links

Sign up online for a virtual consultation with Dr. Lamm, a pioneer in the treatment of bladder and other genitourinary cancers.

Printer Friendly

	ONCOVITE Antioxidant Multivitamins
Dr. Lamm's specially formulated and tested multivitamin tablets deliver a megadose of antioxidants that is beneficial when combined with BCG or other cancer treatment options. Order Oncovite Online

We subscribe to the HONcode principles.
Verify here.

Bladder Cancer Clinical Trials

Despite the success of BCG immunotherapy for superficial bladder cancer, many patients eventually fail. Because BCG prolongs the time to recurrence and progression, patients who fail BCG and other treatments are often at an age when cystectomy is difficult, and with multiple co-morbid conditions, it can even be contra- indicated. We are therefore searching for improved treatments for bladder cancer.

I am pleased to announce that we now have new studies that are hoped will improve the management of bladder cancer. If you have patients that are not responding to standard treatment, please consider one of these options:

Randomized Comparison of Erlinotinib (Tarceva) and Green tea Polyphenone E versus placebo in former smokers. This NCI funded study directed by Arie Beldegrun at UCLA evaluates promising oral agents- the epidermal growth factor inhibitor Tarceva, and an extract of Green tea, both of which have confirmed antitumor activity in animal models. Patients receive standard therapy including, if needed, maintenance BCG while on study. It is a randomized Phase II study and does include a placebo, so it is not appropriate for very high risk patients.
CG0070 Adenovirus Therapy of TA, T1, and CIS in BCG Failure Patients. This Phase I-II study is sponsored by Cell Genesys and utilizes a replication-deficient Adenovirus that is selective for TCC and codes for human GMCSF. A single intravesical instillation is given, with increasing doses with each cohort of 3 patients. Non-muscle invasive tumor must be present, and response is evaluated initially two weeks following administration. Very preliminary results are extremely encouraging. Find out more:
- ClinicalTrials.gov
- Cell Genesys

Follow up is required for patients in each of these studies, but I will send them back to your care as soon as possible unless you wish otherwise. Referrals can be made by calling me at 602 493 6626.

Created: 3/15/2005 | Updated: 3/31/2006

The information available on and through the BCGOncology.com Web site is presented in summary form as a supplement to, and NOT a substitute for, the knowledge, skill, and judgment of qualified physicians and health care professionals. The information on BCGOncology.com has been obtained from sources believed to be accurate and reliable. However, BCG Oncology, PC makes no warranty as to the accuracy, reliability, or completeness of this information. Information accessed on or through BCGOncology.com is neither complete nor exhaustive and does not cover all disabilities, diseases, illnesses, and physical conditions or their management or treatment. Information accessed on and through BCGOncology.com is provided "AS IS" and without warranty, express or implied, including, but not limited to, any implied warranty of merchantability or of fitness for a particular purpose. View our terms of use for more information. Donald L. Lamm, MD is licensed to practice medicine in the state of Arizona, only.

Site design and development by Alamo Web Pros, www.AlamoWebPros.com.